| Nov 14, 2022 |
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
|
|
| Nov 07, 2022 |
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
|
|
| Oct 03, 2022 |
Adamis Announces Review of Strategic Alternatives
|
|
| Sep 21, 2022 |
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
|
|
| Sep 12, 2022 |
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
|
|
| Aug 12, 2022 |
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
|
|
| Aug 10, 2022 |
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
|
|
| Aug 08, 2022 |
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
|
|
| Jul 29, 2022 |
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
|
|
| Jul 29, 2022 |
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
|
|
